KMT2A and plasma cell myeloma: Sustainment of oncogenic MYC expression is associated with MYC super-enhancers in multiple myeloma (MM1.S) and MLL-r leukemia (MLL-AF9/NrasG12D) cells (Lovén et al., 2013; Shi et al., 2013; Shi and Vakoc, 2014).